[Mirizzi syndrome. A rare complication of gallstones diagnosed by endoscopic retrograde cholangiopancreatography]. / Mirizzi's syndrom. En sjoelden komplikation til galdestenssygdom påvist ved endoskopisk retrograd kolangiopankreatografi.

The Mirizzi syndrome is recognized as an external compression of the common hepatic duct by a calculus impacted in the cystic duct. Although it is a rare condition, the diagnosis is important because of the resemblance to malignant strictures in the biliary tract. Two cases diagnosed preoperatively by ERCP are reported.

Treatment of painful osteoporosis with fluoride, calcium, and calciferol.

Fourteen women averaging 69.5 years of age with painful osteoporosis of the spine were treated with sodium fluoride, calcium salts and calciferol. At assessment after 5-19 months of therapy 8 patients were free of pains while in 5 women pains had decreased and mobility improved. One patient had unaltered pains. Side effects were few and mild.

Relief of osteoporotic backache with fluoride, calcium, and calciferol.

In a prospective randomized clinical trial comprising 22 postmenopausal women with backache and a halisteretic spine with crush fracture(s), 12 women completed a 12-week therapy with sodium fluoride, calcium and calciferol and 10 with placebo. A statistically significant improvement (p less than 0.05), evaluated by a four-stage scale on pains, infirmity, and consumption of analgesics, was observed in the actively treated patients.

Jejunal diverticulosis in a family.

The presence of small intestinal diverticula was examined in a family of eight siblings. Six of the siblings had diverticula of the duodenum and/or the jejunoileal tract. Three of them had multiple jejunoileal diverticula, one had two jejunal diverticula, and two had duodenal diverticula. In addition, diseases of an immunologic nature were present in four of the siblings (rheumatoid arthritis, ulcerative colitis, myxoedema following thyroiditis, and non-viral hepatitis).

Long term therapy of pernicious anaemia with the depot cobalamin preparation betolvex.

The value of a depot cobalamin preparation Betolvex (cyanocobalamin-tannin complex suspended in a sesame-oil aluminum-monostearate gel) in the maintenance therapy of pernicious anaemia was investigated in 120 patients followed up for between 8 and 15 years. Complete haematological remission was maintained in all patients, and none developed B12 neuropathy after the start of treatment. No side-effects were observed. The mean values of S-cobalamin were above the reference limits when 1 mg cobalamin was given every 2 months, and high within the reference limits when given at 3 monthly intervals. The cobalamin content in the liver tissue in 2 patients who had received 1 mg cobalamin every 3 months for 6 years revealed normal values. Thus, 1 mg of the depot cobalamin preparation given at intervals of 3 months should provide adequate maintenance therapy in pernicious anaemia.